IRCT138901292641N2 IRCT 2010-04-18 Tehran University Of Medical Sciences Etanercept Versus Placebo in Ocular Manifestations of Behcet's Disease, a single Blind Controlled trial Etanercept Versus Placebo in Ocular Manifestations of Behcet's Disease, a single Blind Controlled trial 2010-06-22 anticipated 80 Complete https://irct.ir/trial/2454 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 4 Ocular involvement in Behcet's disease. Intervention 1: Etanercept 50 mg weekly for one year as well as Methotrexate as 15 mg weekly during the one year plus prednisolone as 30 mg daily, at the entry to the study. The dose will be adjusted and tapered if frank improvement or remission occurs. Intervention 2: Methotrexate as 15 mg weekly during the one year plus prednisolone as 30 mg daily, at the entry to the study. The dose will be adjusted and tapered if frank improvement or remission occurs.